Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the closing of its underwritten public offering of 10,309,280 common shares at US$4.85 per share, generating gross proceeds of approximately US$50 million. Cantor and Barclays served as joint bookrunning managers, with Bloom Burton Securities and Lucid Capital Markets acting as lead managers. The company paid underwriters a cash commission of US$3 million in connection with the offering.
The company plans to use the net proceeds to advance its clinical pipeline, including HLP003 for major depressive disorder, with Phase 3 APPROACH data expected in the fourth quarter of 2026. Additionally, funds will support HLP004 for generalized anxiety disorder and HLP005, as well as working capital and general corporate purposes. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address unmet needs in depression, anxiety, and other mental health conditions. For more details, the full press release is available at https://ibn.fm/bSYLT.
